A Single-dose, Open-label, Randomized, Crossover Study to Assess the Impact of Food on the Pharmacokinetics of Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Administered as a Fixed-dose Combination Tablet, and the Relative Bioavailability
Phase of Trial: Phase I
Latest Information Update: 20 Oct 2017
At a glance
- Drugs Cobicistat/darunavir/emtricitabine/tenofovir alafenamide (Primary) ; Cobicistat; Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide; Darunavir; Emtricitabine/tenofovir alafenamide
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Janssen Sciences Ireland UC
- 21 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Jul 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
- 22 Jun 2015 New trial record